Narcolepsy

New England Journal of Medicine

Volumn 373, Issue 27, 2015, Pages 2654-2662

  Scammell, Thomas E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DEXAMPHETAMINE; HLA DQB1 ANTIGEN; METHYLPHENIDATE; MODAFINIL; OREXIN A; OREXIN B; OXYBATE SODIUM; WAKEFULNESS PROMOTING AGENT; CENTRAL STIMULANT AGENT;

AUTOIMMUNITY; CATAPLEXY; CELL LOSS; CLINICAL FEATURE; COMORBIDITY; DAYTIME SOMNOLENCE; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG INDICATION; EPWORTH SLEEPINESS SCALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HLA DQB1 GENE; HUMAN; HYPOTHALAMUS; NARCOLEPSY; NERVE CELL; NEUROBIOLOGY; PERIODIC LIMB MOVEMENT DISORDER; PRIORITY JOURNAL; REM SLEEP; REVIEW; SLEEP DISORDER ASSESSMENT; SLEEP DISORDERED BREATHING; SLEEP LATENCY TEST; SLEEP QUALITY; SLEEP THERAPY; SLEEP TIME; SLEEP WALKING; SYMPTOMATOLOGY; WEIGHT GAIN; ADULT; CHILD; DIAGNOSTIC ERROR; GENETICS; PATHOPHYSIOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS; CATAPLEXY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; HUMANS; NARCOLEPSY; WAKEFULNESS-PROMOTING AGENTS;

EID: 84952905435     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1500587     Document Type: Review

References (50)

1. Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med 2014; 15: 502-7.
2. Plazzi G, Pizza F, Palaia V, et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain 2011; 134: 3477-89.
3. Wamsley E, Donjacour CE, Scammell TE, Lammers GJ, Stickgold R. Delusional confusion of dreaming and reality in narcolepsy. Sleep 2014; 37: 419-22.
4. Roth T, Dauvilliers Y, Mignot E, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med 2013; 9: 955-65.
5. Pizza F, Tartarotti S, Poryazova R, Baumann CR, Bassetti CL. Sleep-disordered breathing and periodic limb movements in narcolepsy with cataplexy: a systematic analysis of 35 consecutive patients. Eur Neurol 2013; 70: 22-6.
6. Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med 2013; 14: 488-92.
7. Andlauer O, Moore H, Jouhier L, et al. Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency. JAMA Neurol 2013; 70: 891-902.
8. Reiter J, Katz E, Scammell TE, Maski K. Usefulness of a nocturnal SOREMP for diagnosing narcolepsy with cataplexy in a pediatric population. Sleep 2015; 38: 859-65.
9. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005; 28: 113-21.
10. Trotti LM, Staab BA, Rye DB. Testretest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med 2013; 9: 789-95.
11. Goldbart A, Peppard P, Finn L, et al. Narcolepsy and predictors of positive MSLTs in the Wisconsin Sleep Cohort. Sleep 2014; 37: 1043-51.
12. Baumann CR, Mignot E, Lammers GJ, et al. Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep 2014; 37: 1035-42.
13. International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine, 2014.
14. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-85.
15. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998; 95: 322-7.
16. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-76.
17. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-51.
18. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-7.
19. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-74.
20. Crocker A Espa RA Papadopoulou M et al, Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology, 2005, 65, 1184-8
21. Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009; 32: 993-8.
22. Rogers AE, Meehan J, Guilleminault C, Grumet FC, Mignot E. HLA DR15 (DR2) and DQB10602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997; 48: 1550-6.
23. Tafti M, Hor H, Dauvilliers Y, et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 2014; 37: 19-25.
24. Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol 2008; 7: 649-62.
25. Ollila HM, Ravel JM, Han F, et al. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am J Hum Genet 2015; 96: 136-46.
26. Han F, Faraco J, Dong XS, et al. Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet 2013; 9(10): e1003880.
27. Faraco J, Lin L, Kornum BR, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet 2013; 9(2): e1003270.
28. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011; 70: 410-7.
29. Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009; 32: 979-83.
30. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012; 7(3): e33536.
31. Partinen M, Saarenp-HeikkilO, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012; 7(3): e33723.
32. Mahlios J, De la Herr-Arita AK, Mignot E. The autoimmune basis of narcolepsy. Curr Opin Neurobiol 2013; 23: 767-73.
33. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005; 9: 269-310.
34. Estabrooke IV, McCarthy MT, Ko E, et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci 2001; 21: 1656-62.
35. Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005; 25: 6716-20.
36. Blouin AM, Fried I, Wilson CL, et al. Human hypocretin and melanin-concentrating hormone levels are linked to emo-tion and social interaction. Nat Commun 2013; 4: 1547.
37. Diniz Behn CG, Klerman EB, Mochizuki T, Lin SC, Scammell TE. Abnormal sleep/wake dynamics in orexin knockout mice. Sleep 2010; 33: 297-306.
38. Burgess CR, Scammell TE. Narcolepsy: neural mechanisms of sleepiness and cataplexy. J Neurosci 2012; 32: 12305-11.
39. Oishi Y, Williams RH, Agostinelli L, et al. Role of the medial prefrontal cortex in cataplexy. J Neurosci 2013; 33: 9743-51.
40. Burgess CR, Oishi Y, Mochizuki T, Peever JH, Scammell TE. Amygdala lesions reduce cataplexy in orexin knock-out mice. J Neurosci 2013; 33: 9734-42.
41. Meletti S, Vaudano AE, Pizza F, et al. The brain correlates of laugh and cataplexy in childhood narcolepsy. J Neurosci 2015; 35: 11583-94.
42. Donadio V, Liguori R, Vandi S, et al. Lower wake resting sympathetic and cardiovascular activities in narcolepsy with cataplexy. Neurology 2014; 83: 1080-6.
43. Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 2012; 9: 739-52.
44. Lecendreux M. Pharmacological management of narcolepsy and cataplexy in pediatric patients. Paediatr Drugs 2014; 16: 363-72.
45. Scammell TE. Treatment of narcolepsy. UpToDate, 2015 (http://www.uptodate .com/contents/treatment-of-narcolepsy).
46. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43: 88-97.
47. Robertson SD, Matthies HJ, Galli A. A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 2009; 39: 73-80.
48. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540-5.
49. Vienne J, Bettler B, Franken P, Tafti M. Differential effects of GABAB receptor subtypes, gamma-hydroxybutyric acid, and baclofen on EEG activity and sleep regulation. J Neurosci 2010; 30: 14194-204.
50. Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y. Narcolepsy and effectiveness of gammahydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2012; 16: 431-43.